Navigation Links
Lead Therapeutic Candidate for Treatment of Pain from Adynxx, AYX1, Well-Tolerated in Phase 1 Clinical Study
Date:9/5/2012

SAN FRANCISCO, Sept. 5, 2012 /PRNewswire/ -- Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that its lead investigational drug candidate for the prevention of acute and chronic post-operative pain, AYX1, was well-tolerated in a Phase 1 clinical study.

The 30-subject, dose-escalating study evaluated AYX1 in five cohorts of healthy volunteers. AYX1 was well-tolerated at all dose levels, with no serious adverse events reported and no subjects withdrawing from the study.  This positions Adynxx to move AYX1 into a proof-of-concept Phase 2 clinical study later this year. That study will assess the ability of a single administration of AYX1 at the time of surgery to reduce acute pain immediately after surgery, prevent the transition to persistent post-surgical pain, and consequently improve functional recovery. Long-term efficacy of AYX1 after a single administration has been demonstrated in a variety of preclinical pain and functional assessment models.

"We recognize that patients and physicians need new treatment options for post-surgical pain that address its root causes," said Donald Manning, M.D., Ph.D. chief medical officer of Adynxx. "With AYX1, we are aiming to treat post-operative pain as a disease that can be effectively prevented with a single, safe administration at the time of surgery.  Given the urgent need for new pain therapies, we look forward to continuing the advancement of AYX1 and other therapeutics in our pipeline at an aggressive pace."

Added Julien Mamet, Ph.D., founder and chief scientific officer of Adynxx, "We started this company to specifically advance therapeutics that can transform the treatment of pain for patients and physicians. AYX1 has a unique mechanism of action that simultaneously neutralizes multiple molecular mechanisms responsible for the maintenance of pain following surgery. We belie
'/>"/>

SOURCE Adynxx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
2. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
3. Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
4. ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease
5. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
6. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Global Markets for Animal Therapeutics and Diagnostics
9. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
10. Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript
11. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... YORK , Sept. 17, 2014 ... Summary GlobalData,s new report, "Germany Gynecological ... data on the Germany Gynecological Devices market. The ... volume (in units) and average prices (in US ... (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices ...
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 ... of PDL BioPharma, Inc. ("PDL BioPharma" or the "Company") ... Robert S. Willoughby at rswilloughby@pomlaw.com or ... PDL BioPharma and certain of its officers and/or directors ... Exchange Act of 1934.  On September ...
(Date:9/17/2014)... Sept. 17, 2014 Bronstein, Gewirtz & Grossman, ... of the securities of PDL BioPharma, Inc. ("PDL BioPharma" ... Such investors are advised to contact Peretz Bronstein ... at info@bgandg.com or 212-697-6484. ... of its executives violated federal securities laws. ...
Breaking Medicine Technology:Germany Gynecological Devices Market Outlook to 2020 2Germany Gynecological Devices Market Outlook to 2020 3SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PDL BioPharma, Inc. - PDLI 2Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
... Annual Review of the Pharmaceutical Industry and the issues it ... Analyst Christopher Bowe. Bowe,s articles top issues faced by the ... Management" – an examination of how companies will use lifecycle ... corporate value , "Stamp Your Mark and Lead" – ...
... Edwards, Inc. (Nasdaq: MSHL ), an oncology ... targeting cancer metabolism, announced today that it has filed ... and Exchange Commission for a rights offering to existing ... common stock. The Company will announce further details regarding ...
Cached Medicine Technology:Need for Pharma Industry Change, Effective Lifecycle Management and Corporate Brand Reputation Featured in Scrip 100 2Marshall Edwards Announces Rights Offering to Stockholders 2Marshall Edwards Announces Rights Offering to Stockholders 3
(Date:9/18/2014)... 18, 2014 INDIGO Biosciences, a leading ... that it has released a new Human Estrogen-related Orphan ... kits are available. , ERR? is naturally expressed in ... in a variety of other tissue types, including kidney, ... a potential target for anti-obesity therapeutics. Cross-talk between ...
(Date:9/18/2014)... September 18, 2014 Sutter Health’s California ... founder of Dolby Laboratories, by naming the Ray Dolby ... of Ray Dolby provided a founding gift of $21 ... which provides services to patients and families suffering from ... people have been treated at the center since its ...
(Date:9/18/2014)... September 18, 2014 Dentists from ... of highly acclaimed Oxnard All-on-4™ dental implants ... a prosthodontist from the Anacapa Dental Art Institute ... the Canadian Academy of Restorative Dentistry and Prosthodontics ... Reshad’s presentation, “Resection Versus Augmentation: Esthetic Implant Supported ...
(Date:9/18/2014)... 2014 Each year, Norman Regional Hospital ... coincide with National Health IT (NHIT) Week to celebrate ... help Norman Regional show its gratitude, Access, the ... is contributing giveaway items to support their NHIT Week ... and offering free lunches, Norman Regional is spending time ...
(Date:9/18/2014)... Fla (PRWEB) September 18, 2014 According to ... suffer from eczema, with many of them being children. In ... first diagnosed as babies and children. The millions of children ... can be brought on by eczema. A new book has ... who they are and to find relief from the condition ...
Breaking Medicine News(10 mins):Health News:INDIGO Offers Human Estrogen-related Receptor Gamma Assay System 2Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 2Health News:Sutter Health’s CPMC announces Ray Dolby Brain Health Center 3Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 2Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 3Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 4Health News:Oxnard All-on-4™ Dental Implants Expert To Speak Tomorrow at Prestigious Canadian Academy of Restorative 5Health News:Access Helps Norman Regional Hospital Celebrate Its Staff During National Health IT Week 2014 2Health News:New Book Helps Millions of Children Deal With The Emotional Pains of Suffering From Eczema 2
... these conditions go untreated , , MONDAY, May 12 (HealthDay News) ... are bad for your heart, they may also harm your ... to increase one,s risk for retinal vein occlusion, a condition ... more veins carrying blood from the eye to the heart ...
... PITTSBURGH Carnegie Mellon Universitys Justin Y. Newberg and Robert F. Murphy have ... protein patterns in human tissues., ... student in biomedical engineering, described the automated protein pattern recognition tool and ... for cancer diagnosis and therapy. , ...
... Damir Matic, a scientist with Lawson Health Research Institute in ... performed throughout North America and around the world. Matic ... close the gum tissue of cleft palate patients. His research ... is older. , Matic is a craniofacial/plastic surgeon at London ...
... U.S. survey estimates 750,000, mostly males, are hooked , , ... American teens and young adults are problem gamblers according ... on Addictions. , Problem gambling is defined as ... as gambling more than you intended or stealing money ...
... OmniSonics Medical,Technologies, Inc., a developer of advanced medical ... announced today that it has enrolled its,first patient ... a prospective,multi-center U.S. registry study of the company,s ... thrombectomy,for acute limb ischemia (ALI). All patients enrolled ...
... BETHESDA, Md., May 12 Naturlose, a natural sugar,approved as ... found to,reduce the spikes of serum glucose that follow consumption ... (Nasdaq: SPEX ) is currently,studying the efficacy and safety ... trial is ongoing, Spherix has engaged market,research companies to seek ...
Cached Medicine News:Health News:High Blood Pressure, Cholesterol Associated With Eye Disease 2Health News:Carnegie Mellon engineering researchers automate analysis of protein patterns 2Health News:Research shows timing improves cleft palate surgery 2Health News:Problem Gambling Common Among Young Adults 2Health News:OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: